{"id":"W4297981989","doi":"10.1016/j.annonc.2022.08.069","title":"LBA4 Adjuvant nivolumab plus ipilimumab (NIVO+IPI) vs placebo (PBO) for localized renal cell carcinoma (RCC) at high risk of relapse after nephrectomy: Results from the randomized, phase III CheckMate 914 trial","year":2022,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":false,"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Bayer Fund; Ipsen Biopharmaceuticals; Janssen Pharmaceuticals; Sanofi Australia; AstraZeneca; Meso Scale Diagnostics; Merck; Astellas Pharma US; Pfizer; Bristol-Myers Squibb","keywords":"Medicine; Nivolumab; Ipilimumab; Renal cell carcinoma; Internal medicine; Oncology; Adjuvant; Nephrectomy; Placebo; Urology; Immunotherapy; Cancer; Kidney; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[{"model":"gemma","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"},{"model":"gpt","categories":[],"domain":null,"study_design":"randomized_trial","genre":"empirical","about_ca_system":false,"about_ca_topic":false,"confidence":"high","status":"direct model label, unvalidated"}],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001165185,0.001296793,0.002034051,0.0003050952,0.000299525,0.001152021,0.0009161347,0.001144591,0.006682351],"category_scores_gemma":[0.00140523,0.000482616,0.002113065,0.0003009628,0.0008736428,0.0008454315,0.0004690369,0.00306657,0.001125113],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009443603,"about_ca_system_score_gemma":0.001077316,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001687193,"about_ca_topic_score_gemma":0.003310087,"domain_scores_codex":[0.9995895,0.000225113,0.00001651152,0.00006707585,0.00002734331,0.00007441108],"domain_scores_gemma":[0.9994785,0.0001562835,0.0001318699,0.00004417917,0.00002660173,0.0001626158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9672937,0.002933311,0.0007838131,0.0007088126,0.001664754,0.00002360686,0.00003368003,0.0006830706,0.002233145,0.0001406191,0.001202437,0.02229915],"study_design_scores_gemma":[0.94175,0.04945613,0.003520966,0.00008359442,0.002010599,0.00004269035,0.00003770117,0.0007595138,0.0006949573,0.0003684772,0.001252263,0.00002321132],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.986845,0.006408552,0.0004453082,0.0009073212,0.0005349627,0.0008057389,0.001092933,0.0001567015,0.002803534],"genre_scores_gemma":[0.9891272,0.002416401,0.0008413371,0.0009794151,0.0002852691,0.0009280321,0.001421918,0.00003172688,0.003968671],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006682351,"threshold_uncertainty_score":0.02235466,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0409074776014903,"score_gpt":0.3162637482691317,"score_spread":0.2753562706676415,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}